SpliceTacs Bio

Partnership opportunities
-Collaborations for further development are welcomed.
For Contact:
Technology Transfer:
INNOVECTIS GmbH
Altenhöferallee 5
60438 Frankfurt am Main, Germany
Phone: +49 (0)69 2561632-0
christoph.emmerich@innovectis.de

Technology
SpliceTACs are small-molecule degraders designed to selectively remove USP39, a protein that supports accurate RNA splicing.
By linking an allosteric USP39-binding molecule to a recruiter of the cell’s protein degradation machinery, the technology enables targeted breakdown of a protein that is difficult to address with conventional inhibitors.
This approach aims to exploit the dependence of certain cancer cells on reliable RNA processing.

Application
The initial therapeutic focus is hepatocellular carcinoma (HCC), particularly advanced tumors with high USP39 expression.
Targeted USP39 degradation aims to disrupt RNA processing and impair tumor cell survival.
Further applications may include other cancers that depend on USP39 and are vulnerable to splicing disruption.

Technology stage
The technology is at the preclinical proof-of-concept stage.
Prototype degraders have demonstrated potent USP39 degradation in cellular assays, with a reported DC50 of approximately 1 nM after 24 hours, and antitumor activity in a preclinical HCC model.
Next steps include lead optimization, pharmacokinetic and pharmacodynamic characterization, biomarker validation, and further efficacy and safety studies.
